Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02922335 · ClinicalTrials.gov registry record · NA
Multisystemic Therapy-Emerging Adults Trial
A NA study, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- NA
- Development phase
- 193
- Enrollment target
NCT02922335: Completed NA study, sponsored by University of Massachusetts, Worcester.
NCT02922335 is a NA study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 193 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02922335, a NA study, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- NA
- Development phase
- 193 participants
- Enrollment target
Study Summary
This study's purpose is to test the effectiveness of a promising intervention for emerging adults (EAs) with mental illness (MI) and serious antisocial behavior in achieving the ultimate outcome of reduced antisocial behavior, and proximal intermediate outcomes. Multisystemic Therapy-Emerging Adults (MST-EA) is an adaptation of MST, a well-established, effective intervention for antisocial behavior in adolescents.
Primary Outcome
Changes from the Baseline in offending, measured in the number of offenses in the Self-Report Offending Scale, during the 16 months post-baseline.
Interventions
- BEHAVIORAL Enhanced Treatment as Usual
- BEHAVIORAL Multisystemic Therapy for Emerging Adults
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2016-09-01 |
| Est. Completion | 2023-01-31 |
| Phase | NA |
What the finished NCT02922335 record still lists
NCT02922335 is an interventional study that assigns participants to a tested intervention. The registered 193 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 2 interventions - of which Enhanced Treatment as Usual is the first listed.
NCT02922335 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02922335 about?
NCT02922335 is a clinical study titled "Multisystemic Therapy-Emerging Adults Trial". This study's purpose is to test the effectiveness of a promising intervention for emerging adults (EAs) with mental illness (MI) and serious antisocial behavior in achieving the ultimate outcome of reduced antisocial behavior, and proximal intermediate outcomes. Multisystemic Therapy-Emerging Adults...
What is the current status of trial NCT02922335?
This trial is currently completed. It is a NA study. The enrollment target is 193 participants. The study started on 2016-09-01. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT02922335?
The interventions under investigation include: Enhanced Treatment as Usual (BEHAVIORAL), Multisystemic Therapy for Emerging Adults (BEHAVIORAL).
Who is sponsoring clinical trial NCT02922335?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02922335's enrollment target sits among peer trials
193 569th of 2000 higher than 1,431 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06226220 · 193 participants · NA
Percutaneous Nerve Evaluation Trial Time
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI